Making Sense of MAVEs: How Machine Learning and Human Expertise are Improving Variant Classification and Clinical Actionability

Automation and AI have the power to transform gene variant classification, yielding deeper insights, lower rates of variants of uncertain significance (VUS) and improved clinical actionability. This webinar explores the benefits of multiplexed assays of variant effects (MAVEs) to systematically characterize variant effects on molecular functions, and how scientists are incorporating those data to reclassify variants, reduce VUS and enhance clinical actionability. Speakers: Chris Tan, MS, CGC, Senior Scientific Program Manager, LabcorpDavid Stafford, PhD, Research Scientist, Genetic Insights Group, Labcorp Samskruthi Padigepati, MS, Senior Machine Learning Scientist, Labcorp 

The Importance of Human Expertise in AI-Informed Variant Interpretation Workflows

This webinar explores how scientists guide the development, validation and responsible use of automation and AI tools to enhance accuracy and scalability of clinical variant classification. Learn how AI draws on diverse data such as clinical case information, literature and functional evidence to improve classification confidence and reduce rates of variants of uncertain significance (VUS). This session also emphasizes the role of human expert oversight in translating these innovations into meaningful clinical outcomes. Speakers: Yuya Kobayashi, PhD, Development and Translational Scientist, Genetic Insights Group, LabcorpMichelle Zeman, PhD, Associate Director of Product Management, Labcorp  

Inside the future of genetics: How leaders are scaling precision medicine across care settings

Genetics is no longer reserved for rare conditions or niche specialties. Genomic insights are shaping real-time treatment decisions at health systems nationwide, but expanding this impact across all clinical settings still presents major hurdles.

Diverse prenatal patient populations, including triplet and multiple gestation pregnancies, can only be screened using a single cfDNA screening test, Labcorp's MaterniT® 21 PLUS.

Diverse prenatal patient populations, including triplet and multiple gestation pregnancies, can only be screened using a single cfDNA screening test, Labcorp's MaterniT® 21 PLUS.

Bridging the gap: Reaching the underserved in cervical cancer screening and the vital role of primary care physicians

Each year around 13,000 women are diagnosed with cervical cancer and more than 4,000 women die. 50% of all new cervical cancers are in women who have never been screened or have not been screened in the previous 5 years of their lives.1